Roche added to its obesity portfolio by licensing Hanmi Pharmaceutical’s early-stage urocortin-2 analog HM-17321, agreeing to pay $190 million up front with potential total payments of up to $2.3 billion. Media reports describe the asset as intended to promote weight loss while preserving lean mass, targeting a mechanism distinct from incretin-based competitors in the category. Roche’s deal terms exclude South Korea, where Hanmi is based. For obesity drugmakers and pipeline planners, the transaction reflects continued capital reallocation toward differentiated pharmacology rather than another direct entrant into GLP-1-centric strategies.